passing the baton

Pietro Crovetto, VP Global Inhalation Strategy at Lupin Pharmaceuticals with vast experience from the international pharmaceutical industry at various prominent positions within commerce, marketing, strategy, and business development, for a variety of companies including Novartis, Chiesi, ALK Abelló and Teva Pharmaceuticals. Pietro has been a client to Opticom for over 10 years, both at previous positions and now, working for Lupin. He gives the background to his experiences with Opticom International Research, focusing on the latest Lupin project Opticom conducted, that he was personally involved in.

PietroLupin
Pietro Crovetto VP, Global Inhalation Strategy, Lupin Pharmaceuticals

The main objective was to map the unmet needs of healthcare professionals and patients within asthma and COPD in terms of currently available innovative products’ attributes, in order to develop Lupin’s product so that it would satisfy those unmet needs better than competitor products.

Another aim was to enable Lupin to differentiate its product, including the services and monitoring systems offered, from existing alternatives and competitor products.

In the end, the main goal was to create a product that improves patient quality of life through ease-of-use, thus leading to improved compliance and lower treatment cost, something which would also lead to obvious advantages for healthcare professionals as well as payers.

The targeted markets in this project were the United Kingdom, Germany, France, Italy and Spain. The information was gathered in two modules, starting with desk research identifying relevant respondents with whom in-depth telephone interviews were then conducted.

Describing this project, Pietro explains that his idea was to monitor the emerging changes in therapeutic approaches and especially the interest in new combination products within the treatments of asthma and COPD. Basically to get a European overview of the present situation and to identify whether their designed new combination product was going to be successful or not and whether there were any differences across the European markets in this respect.

Pietro continues: I wanted to benchmark, to interview “real” clinicians, not opinion leaders, because there is a critical difference here. Opinion leaders are up to speed with the latest research and treatment options, as they often have done this research themselves, while clinicians might very well have heard about new stuff, after all they are specialists, but they are not necessarily as enthusiastic to adopt something new as the opinion leaders.

Choosing Opticom to supply Lupin with the market research was based on a combination of different factors; first of all good experiences in the past, resulting in a strong sense of reliability. According to Pietro, a key asset of Opticom is the fact that they offer both a very knowledgeable staff who understand the complex medical issues as well as their multilingual skills: “It helps a lot when we do not have to explain so much to a supplier and more time can be spent on the actual research, on the specifics of the projects!”

Sometimes the challenge with international market research, Pietro explains, is that you end up with the “Chinese whisper”, meaning I brief you, you brief somebody else and then that person briefs somebody else in turn, and then at the end of the day, you are not sure what went missing and where. So based on that, the two main points on why to choose Opticom are definitely their knowledge of the field and its multilingual staff based in one office. A third reason, according to Pietro, actually equally important: every time he has worked with Opticom, the adopted strategy has been to do 20-30% of the interviews, then pause for evaluation of the questionnaire, the response and answers so far: simply put: is it working? The Project Managers at Opticom are very flexible here and that is greatly appreciated, to optimize the quality of the output.

Concerning what the market insights provided by Opticom have meant to Lupin and what has been most valuable, Pietro points to the decision to invest in particular combinations of treatments, emphasizing that this is the most critical stage in their R&D and business development without going into specifics.

The results have also influenced their business decision-making, being added into their forecasting, because even if the research was qualitative, it was still very helpful to better understand what direction the market was taking. All in all, the insights have been used on several levels and according to Pietro, further investment decisions within asthma and COPD are definitely going to be based on the results from this research as well.

Asked about the return of investment, Pietro confesses: “To be honest, we didn’t count on ROI, but it was not at all expensive considering the huge amounts that have been spent on this treatment area, so the money we spent with Opticom was definitely worth it, more than worth it!”

According to Pietro, the main benefits of this specific project were that his team at Lupin got an additional level of insights on a practical level: there is a crucial difference between the people who work on the front line with patients and the opinion leaders, the high science: “We need to have a balance of both because we cannot ignore high science but at the end of the day we need to understand nurses on the floor, having issues reconstituting the product, for example. That is really a very valuable difference to us and something that Opticom understands. So I am very satisfied, more than satisfied and very happy with the co-operation with Opticom!”

Download PDF

The Swedish Childhood Cancer Foundation Gala 2017

For the third year in a row, The Swedish Childhood Cancer Foundation arranged a gala-night with the main purpose to get TV- viewers to become children supporters/monthly donors to support children in the battle against cancer. The Swedish Childhood Cancer Foundation also offered companies and private persons to make large donations by telephone during the gala. The gala was broadcasted live from Berns Salonger in central  Stockholm on Swedish channel 5, 2 October between 20.00-22.00.

Team Opticom, Alumni, Snille Networks, Mattias Claesson and Robin Arding had the pleasure to handle the set-up and receiving of large donations at GT 30 (Helio) .

It was a great success: The Swedish Childhood Cancer Foundation gala 2017 raised more than twice as many monthly donors as the previous year and broke the record for big donations!

Opticom Group is proud and grateful to be a part of the success!

Download PDF

Almedalen 2017 logos website

 

Wisby Strands Veranda & Taverna

 

After Work Almedalen

Onsdag 5 juli 2017 kl. 17:00 – 19:00

Wisby Strands Veranda

Opticom, Adxto & Mimerex
arrangerar även i år ett gemensamt mingel för våra kunder.
Vi bjuder på rosé, tilltugg samt ett lättsamt samkväm med kollegor i branschen.
Vi kommer vid tillfället att informera om våra verksamheter.

Vi hoppas att du vill komma och ser fram emot att träffa dig!

Varmt välkommen önskar
Carl Michael Bergman, Helena Östregård, Pontus Torstensson och kollegor

Tyvärr har vi ett begränsat antal platser, så anmäl dig gärna så snart som möjligt: Anmälan
Om du får förhinder, meddela oss gärna via: almedalen@opticom.se

Vill du veta mer om vad vi på Opticom, Adxto och Mimerex arbetar med? Kontakta oss gärna eller besök våra hemsidor:

Carl Michael Bergman, VD, Opticom: carl.michael@opticom.se  Opticom Group Opticom International Research

Helena Östregård, VD, Adxto helena.ostregard@adxto.com Adxto

Pontus Torstensson, VD, Mimerex pontus.torstensson@mimerex.com Mimerex

 

Download PDF

Health Logos June 2017

We at Opticom are happy and grateful for the valuable partnerships and inspiring journey we have been part of the last 30 years!

We thank all our clients for trusting Opticom with important projects, and we also thank all of our co-workers and business partners for their hard work and commitment to Opticom.

Our roots stem from research and analysis, which has provided our clients with true customer understanding. This understanding has served as the foundation for decisions that aim at creating substantial value for our customers in Health, Forest Products and Industrial Goods. Numerous client testimonials show that research pays off.

Over the years, we have added Consulting to our offering, helping our clients to use real-world insights to improve business decision making. Research and Consulting are the two disciplines that we have built our success upon: it has been our privilege to serve an incredible list of globally leading companies.

In 2014, we added Communication as the third leg of our business, and thus today we at Opticom Group feel honoured to offer global research, consulting and communication.

Today we are very much looking forward to the next 30 years and beyond. We can assure you that we will continue to be passionate about understanding your key challenges and in finding solutions that deliver true value.

Download PDF
iStock_000007042359_Large

Francesco De Rosa, with vast experience from the international pharma industry at various prominent positions within sales, brand and business managing, gives the background to one of his first experiences with Opticom International Research: “At the time, I had taken over a very important Pfizer brand with a five-year legacy of declining market shares and I needed to get a 360 degree understanding of the decision-making process within the growth hormone therapy area” he explains and continues: “My scope was clear: bend the trend!”.

To gain this crucial understanding, Francesco turned to Opticom, a company which had previously delivered very good and useful results in projects for another pharmaceutical brand he had worked with. In the project of close co-operation that followed, Opticom conducted about 100 qualitative interviews with parents, paediatricians, and nurses to understand their different needs and reasoning within this therapy area.

The research discovered many “leaks” that delayed children’s access to treatment as well as large regional differences. Based on Opticom’s comprehensive analysis of the patient journey and treatment rationales, Francesco was able to change his company’s strategy, including a relocation of resources, better aligned to the customer landscape, as well as to improve communication around the value of treatment. In addition, the team could optimize its different support tools to physicians, nurses and parents, in order to facilitate earlier diagnose and better compliance.

Furthermore, Francesco and his colleagues came up with an improved treatment device to deal with an issue rated very important among respondents in the survey: Ease-of-use.

He describes the direct impact of this new, very valuable market knowledge: “Thanks to the new insights we designed a new device for the treatment of growth hormones deficiencies among children in order to meet the single most important factor in the choice of treatment: Easy-of-use of the device. This resulted in a patent available in more than 100 countries worldwide”.

As a result of the new strategy, the brand soon turned decline into growth and has been continuing this positive development ever since.

According to Francesco, the generation of updated customer insights is key to their business. Understanding both traditional and non-traditional stakeholders, their needs, as well as the patient journey and the decision-making process is fundamental in forming a successful business strategy.

In these situations you need a consulting company with a strong focus on quality, and with a thorough process for both research as well as analysis that delivers real and actionable results. That is where Opticom comes in as a very valuable partner with the staff’s vast knowledge and experience of the pharma industry:  “They are methodical in their understanding of customer needs and in making sure that the setup of the project, from the very start to result implementation, is consistent and with a great focus on details and delivery” says Francesco, who would definitely engage Opticom again to gain strategic insights and/or to facilitate optimized communication.

Download PDF